Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients

Autor: Collen, C. ^*, Christian, N., Schallier, D., Meysman, M., Duchateau, M., Storme, G., De Ridder, M.

Publikováno v: In Annals of Oncology October 2014 25(10):1954-1959

Tolerance of adjuvant letrozole outside of clinical trials

Autor: Fontaine, C., Meulemans, A., Huizing, M., Collen, C., Kaufman, L., De Mey, J., Bourgain, C., Verfaillie, G., Lamote, J., Sacre, R., Schallier, D., Neyns, B., Vermorken, J., De Grève, J.

Publikováno v: In The Breast 2008 17(4):376-381

A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)

Autor: Schallier, D., Neyns, B., Fontaine, C., Steene, J. Vande, De Mey, J., Meysman, M., De Grève, J.

Publikováno v: In Lung Cancer 2007 56(2):247-254

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Autor: Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee, CheckMate 025 Investigators, Schallier, D, Schallier, Denis

Publikováno v: Motzer, R J, Escudier, B, McDermott, D F, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Procopio, G, Plimack, E R, Castellano, D, Choueiri, T K, Gurney, H, Donskov, F, Bono, P, Wagstaff, J, Gauler, T C, Ueda, T, Tomita, Y, Schutz, F A, Kollmannsberger, C, Larkin, J, Ravaud, A, Simon, J S, Xu, L-A, Waxman, I M, Sharma, P & CheckMate 025 Investigators 2015, ' Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 373, no. 19, pp. 1803-13 . https://doi.org/10.1056/NEJMoa1510665
NEW ENGLAND JOURNAL OF MEDICINE

BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a331349b83f68cef9dbae547a13cd8e3
https://www.ncbi.nlm.nih.gov/pubmed/26406148